NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog
What will China’s new dual-list mechanism mean for launch timing, pricing risks, and long-term market potential for innovative drugs?
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List
The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China
This Q&A explores the growing gap between global pharma strategies and China’s payer priorities—offering a self-assessment tool for internal alignment, and insights into risks and opportunities in the commercial catalog pathway.
Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines
Gain practical tools and insight to navigate China’s C-List and Commercial Catalog—and make informed decisions on product positioning across emerging access pathways.
NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China
This Access360 Executive Briefing lays the groundwork for understanding China’s shift toward value-based pricing, deeper insurance–medicine–care integration, and broader market transformation driven by its national commercial insurance catalog initiatives.
China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback
As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List
Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines
The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
Pioneering Value-Based Care in China: A Conversation with Dr. Felix Lee, Co-CEO of The GBA Healthcare Group
This success story emphasizes the importance of aligning healthcare innovation with a nation's infrastructure and social security framework to ensure practical, scalable, and sustainable care delivery and payment models.
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations
These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
